Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - telmisartan, quantity: 80 mg - tablet - excipient ingredients: sodium stearylfumarate; magnesium stearate; mannitol; meglumine; sodium hydroxide; povidone - apo-telmisartan is indicated for:,treatment of hypertension,prevention of cardiovascular morbidity and mortality in patients 55 years or older with coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic attack or high risk diabetes with evidence of end organ damage (see clinical trials)

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ethinylestradiol, quantity: 20 microgram; drospirenone, quantity: 3 mg - tablet, film coated - excipient ingredients: lactose; magnesium stearate; povidone; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - this medicine is indicated for use as: ? an oral contraceptive. ? treatment of moderate acne vulgaris in women who seek oral contraception. ? treatment of symptoms of premenstrual dysphoric disorder (pmdd) in women who have chosen oral contraceptives as their method of birth control. the efficacy of drospirenone 3 mg /ethinylestradiol 20 ?g for pmdd was not assessed beyond 3 cycles. drospirenone 3 mg /ethinylestradiol 20 ?g has not been evaluated for treatment of pms (premenstrual syndrome), see section 5.1 pharmacodynamic properties - clinical trials.

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - perindopril erbumine, quantity: 8 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate; hydrophobic colloidal silica anhydrous; chlorophyllin-copper complex aluminium lake - indosyl mono is indicated for: the treatment of hypertension; indosyl mono is indicated for: the treatment of heart failure. in such patients it is recommended that indosyl mono be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of indosyl mono has not been demonstrated for new york heart association category iv patients) indosyl mono is indicated for: patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - perindopril erbumine, quantity: 4 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; hydrophobic colloidal silica anhydrous; magnesium stearate - indosyl mono is indicated for: the treatment of hypertension; indosyl mono is indicated for: the treatment of heart failure. in such patients it is recommended that indosyl mono be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of indosyl mono has not been demonstrated for new york heart association category iv patients) indosyl mono is indicated for: patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - perindopril erbumine, quantity: 2 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; hydrophobic colloidal silica anhydrous; magnesium stearate - indosyl mono is indicated for: the treatment of hypertension; indosyl mono is indicated for: the treatment of heart failure. in such patients it is recommended that indosyl mono be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of indosyl mono has not been demonstrated for new york heart association category iv patients) indosyl mono is indicated for: patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

United States - English - NLM (National Library of Medicine)

viatrexx bio incorporated - adrenal gland (6x, 200k), aldosterone (15x, 200k), androsterone (15x, 200k), camp / adenosinum cyclophosphoricum (6x, 200k), cholesterinum (6x, 200k), dhea (6x, 200k), growth hormone (4c, 200k), hypothalamus (8x, 200k), melatonin (4c, 200k), pancreas (6x, 200k), pineal (6x, 200k), pituitary (6x, 200k), prostate (6x, 200k), testis (6x, 200k), testosterone (6x, 200k), thalamus (6x, 200k), thymus (6c, 200k), thyroid gland (200k) - to help support the structure & function of the male endocrine system

United States - English - NLM (National Library of Medicine)

carilion materials management - metoclopramide hydrochloride (unii: w1792a2rvd) (metoclopramide - unii:l4yeb44i46) - metoclopramide 5 mg - the use of metoclopramide tablets is recommended for adults only. therapy should not exceed 12 weeks in duration. metoclopramide tablets are indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy. the principal effect of metoclopramide is on symptoms of postprandial and daytime heartburn with less observed effect on nocturnal symptoms. if symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of a 12 week trial using doses of 15 mg q.i.d. as there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically. metoclopramide tablets are indicated for the relief of sympt

United States - English - NLM (National Library of Medicine)

carilion materials management - trandolapril (unii: 1t0n3g9crc) (trandolaprilat - unii:rr6866vl0o) - trandolapril 1 mg - trandolapril tablets are indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensive medication such as hydrochlorothiazide. trandolapril tablets usp are indicated in stable patients who have evidence of left-ventricular systolic dysfunction (identified by wall motion abnormalities) or who are symptomatic from congestive heart failure within the first few days after sustaining acute myocardial infarction. administration of trandolapril to caucasian patients has been shown to decrease the risk of death (principally cardiovascular death) and to decrease the risk of heart failure-related hospitalization (see clinical pharmacology -heart failure or left-ventricular dysfunction post myocardial infarction for details of the survival trial). trandolapril tablets are contraindicated in patients who are hypersensitive to this product, in patients with hereditary/idiopathic angioedema and in patients with a history of angioedema related to previous treatment with an a

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - perindopril erbumine, quantity: 8 mg - tablet, uncoated - excipient ingredients: lactose; magnesium stearate - treatment of hypertension. treatment of heart failure. in such patients it is recommended that perindopril be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril have not been demonstrated for new york heart association category iv patients). patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of nonfatal myocardial infarction or cardiac arrest.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - perindopril erbumine, quantity: 4 mg - tablet, uncoated - excipient ingredients: lactose; magnesium stearate - treatment of hypertension. treatment of heart failure. in such patients it is recommended that perindopril be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril have not been demonstrated for new york heart association category iv patients). patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of nonfatal myocardial infarction or cardiac arrest.